Award for Achievement in the field of NSCLC Ceremony (supported by AstraZeneca) followed by Grand Round "How to diagnose and manage NSCLC with the new drugs" - an interactive session
Grand roundChairs: J. Cadranel (Paris, France), J-P. Sculier (Brussels, Belgium)
Aims: The therapeutic management of advanced NSCLC underwent a therapeutic revolution in recent years. The use of TKI specific to addictive molecular abnormalities (EGFR mutations, ALK translocation) in patients whose tumours carried such mutations has been associated with major and prolonged objective response. The use of platinum-based doublets, and especially the development of maintenance strategies, also provide therapeutic benefit in overall survival. It is important that pulmonologists and oncolo-pneumologists can integrate this data into their clinical practice. The aim of this session will be to illustrate by exemplary clinical cases the diagnostic approach of addictive mutations, the practical use of TKI, what to do in case of toxicities and progression, and finally to address the concepts of the continuation maintenance or switch maintenance.